March 11, 2021
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:Ada Sarmento
Re:Silence Therapeutics plc
Registration Statement on Form F-1
Filed March 11, 2021
File No. 333-254021
Acceleration Request
Requested Date: March 12, 2021
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-254021) (the “Registration Statement”), to become effective on March 12, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant may orally request via telephone call to the Commission’s staff. The Registrant hereby authorizes Joshua A. Kaufman of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Joshua A. Kaufman of Cooley LLP at (212) 479-6495.
[Signature page follows]
Very truly yours,
SILENCE THERAPEUTICS PLC
By: /s/ Mark Rothera
Mark Rothera
President and Chief Executive Officer
cc:Craig Tooman, Silence Therapeutics plc
Joshua Kaufman, Cooley LLP
Divakar Gupta, Cooley LLP
Claire Keast-Butler, Cooley LLP
Elizabeth Schauber, Cooley LLP
